SiBone (SIBN)
(Delayed Data from NSDQ)
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Zacks News
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
by Zacks Equity Research
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.
Syneos Health (SYNH) to Go Private, Reports Q2 Performance
by Zacks Equity Research
Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
Can Conifer Weakness Affect Tenet Healthcare's (THC) Q2 Earnings?
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Higher Costs Affect HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to reflect increased patient volumes, occupancy rate and cost of supplies.
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.
What's in Store for Canopy Growth (CGC) in Q1 Earnings?
by Zacks Equity Research
Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.
Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.
Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.
Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
by Zacks Equity Research
In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.
Align Technology's (ALGN) New Pacts, Innovation Aid Growth
by Zacks Equity Research
Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.
Labcorp (LH) Completes Strategic Deal With Jefferson Health
by Zacks Equity Research
Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.
Will Carelon Growth Aid Elevance Health's (ELV) Q2 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect rising memberships in Medicare Advantage, Medicaid, Vision and Dental Administration businesses.
Quest Diagnostics (DGX) Brings New Test for Prostate Cancer
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.
Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health
by Zacks Equity Research
Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.
Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System
by Zacks Equity Research
Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.
Penumbra (PEN) Gains on New Launches Amid Currency Headwind
by Zacks Equity Research
Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.